Suppr超能文献

在一个大型多机构原发性T1高级别/3级膀胱癌患者队列中,再次经尿道切除术后残余T1高级别病变的预测因素。

Predictors of Residual T1 High Grade on Re-Transurethral Resection in a Large Multi-Institutional Cohort of Patients with Primary T1 High-Grade/Grade 3 Bladder Cancer.

作者信息

Ferro Matteo, Di Lorenzo Giuseppe, Buonerba Carlo, Lucarelli Giuseppe, Russo Giorgio Ivan, Cantiello Francesco, Farhan Abdal Rahman Abu, Di Stasi Savino, Musi Gennaro, Hurle Rodolfo, Vincenzo Serretta, Busetto Gian Maria, De Berardinis Ettore, Perdonà Sisto, Borghesi Marco, Schiavina Riccardo, Almeida Gilberto L, Bove Pierluigi, Lima Estevao, Grimaldi Giovanni, Matei Deliu Victor, Mistretta Francesco Alessandro, Crisan Nicolae, Terracciano Daniela, Paolo Verze, Battaglia Michele, Guazzoni Giorgio, Autorino Riccardo, Morgia Giuseppe, Damiano Rocco, Muto Matteo, Rocca Roberto La, Mirone Vincenzo, de Cobelli Ottavio, Vartolomei Mihai Dorin

机构信息

Division of Urology, European Institute of Oncology, Milan, Italy.

Department of Clinical Medicine and Surgery, Federico II University of Naples, Naples, Italy.

出版信息

J Cancer. 2018 Oct 20;9(22):4250-4254. doi: 10.7150/jca.26129. eCollection 2018.

Abstract

The aim of this multi-institutional study was to identify predictors of residual high-grade (HG) disease at re-transurethral resection (reTUR) in a large cohort of primary T1 HG/Grade 3 (G3) bladder cancer patients. A total of 1155 patients with primary T1 HG/G3 bladder cancer from 13 academic institutions that underwent a reTUR within 6 weeks after first TUR were evaluated. Logistic regression analysis was performed to assess the association of predictive factors with residual HG at reTUR. Residual HG cancer was found in 288 (24.9%) of patients at reTUR. Patients presenting residual HG cancer were more likely to have carcinoma in situ (CIS) at first resection (p<0.001), multiple tumors (p=0.02), and tumor size larger than 3 cm (p=0.02). Residual HG disease at reTUR was associated with increased preoperative neutrophil-to-lymphocytes ratio (NLR) (p=0.006) and body mass index (BMI)>=25 kg/m. On multivariable analysis, independent predictors for HG residual disease at reTUR were tumor size >3cm (OR = 1.37; 95% CI: 1.02-1.84, p=0.03), concomitant CIS (OR 1.92; 95% CI: 1.32-2.78, p=0.001), being overweight (OR= 2.08; 95% CI: 1.44-3.01, p<0.001) and obesity (OR 2.48; 95% CI: 1.64-3.77, p<0.001). A reTUR in high grade T1 bladder cancer is mandatory as about 25% of patients, presents residual high grade disease. Independent predictors to identify patients at risk of residual high grade disease after a complete TUR include tumor size, presence of carcinoma in situ, and BMI >=25 kg/m.

摘要

这项多机构研究的目的是在一大群原发性T1高级别(HG)/3级(G3)膀胱癌患者中,确定再次经尿道切除术(reTUR)时残留高级别疾病的预测因素。对来自13个学术机构的1155例原发性T1 HG/G3膀胱癌患者进行了评估,这些患者在首次经尿道膀胱肿瘤电切术(TUR)后6周内接受了reTUR。进行逻辑回归分析以评估预测因素与reTUR时残留HG的关联。在reTUR时,288例(24.9%)患者发现残留HG癌。出现残留HG癌的患者在首次切除时更有可能存在原位癌(CIS)(p<0.001)、多发肿瘤(p=0.02)和肿瘤大小大于3 cm(p=0.02)。reTUR时残留HG疾病与术前中性粒细胞与淋巴细胞比值(NLR)升高(p=0.006)和体重指数(BMI)>=25 kg/m²有关。多变量分析显示,reTUR时HG残留疾病的独立预测因素为肿瘤大小>3cm(OR = 1.37;95%CI:1.02-1.84,p=0.03)、合并CIS(OR 1.92;95%CI:1.32-2.78,p=0.001)、超重(OR= 2.08;95%CI:1.44-3.01,p<0.001)和肥胖(OR 2.48;95%CI:1.64-3.77,p<0.001)。对于高级别T1膀胱癌患者,reTUR是必需的,因为约25%的患者存在残留高级别疾病。识别完全TUR术后有残留高级别疾病风险患者的独立预测因素包括肿瘤大小、原位癌的存在以及BMI>=25 kg/m² 。

相似文献

3
Clinical and pathological predictors of persistent T1 HG at second resection.
Urologia. 2023 Aug;90(3):482-490. doi: 10.1177/03915603231181619. Epub 2023 Jun 21.
5
Repeat Transurethral Resection in Non-muscle-invasive Bladder Cancer: A Systematic Review.
Eur Urol. 2018 Jun;73(6):925-933. doi: 10.1016/j.eururo.2018.02.014. Epub 2018 Mar 6.
6
Risk factors for residual disease at re-TUR in a large cohort of T1G3 patients.
Actas Urol Esp (Engl Ed). 2021 Jul-Aug;45(6):473-478. doi: 10.1016/j.acuroe.2020.08.014. Epub 2021 Jun 17.
7
Do we need repeat transurethral resection after en bloc resection for pathological T1 bladder cancer?
BJU Int. 2023 Feb;131(2):190-197. doi: 10.1111/bju.15760. Epub 2022 May 13.
9
Validation of Neutrophil-to-lymphocyte Ratio in a Multi-institutional Cohort of Patients With T1G3 Non-muscle-invasive Bladder Cancer.
Clin Genitourin Cancer. 2018 Dec;16(6):445-452. doi: 10.1016/j.clgc.2018.07.003. Epub 2018 Jul 6.
10

引用本文的文献

3
Impact of multi-parameter images obtained from dual-energy CT on radiomics to predict pathological grading of bladder urothelial carcinoma.
Abdom Radiol (NY). 2024 Dec;49(12):4324-4333. doi: 10.1007/s00261-024-04516-0. Epub 2024 Aug 12.
4
Do we need a re-TUR after en bloc resection of T1 stage bladder cancer?
World J Urol. 2024 Aug 8;42(1):475. doi: 10.1007/s00345-024-05175-y.
5
Role of Maximal Transurethral Resection Preceding Partial Cystectomy for Muscle-Invasive Bladder Cancer.
Ann Surg Oncol. 2024 Feb;31(2):1384-1392. doi: 10.1245/s10434-023-14449-5. Epub 2023 Oct 26.
7
Clinical and pathological predictors of persistent T1 HG at second resection.
Urologia. 2023 Aug;90(3):482-490. doi: 10.1177/03915603231181619. Epub 2023 Jun 21.
8
A prognostic model for bladder cancer based on cytoskeleton-related genes.
Medicine (Baltimore). 2023 Apr 25;102(17):e33538. doi: 10.1097/MD.0000000000033538.

本文引用的文献

1
Comparison of 10-year overall survival between patients with G1 and G2 grade Ta bladder tumors.
Medicine (Baltimore). 2018 Apr;97(16):e0522. doi: 10.1097/MD.0000000000010522.
2
Role of Restaging Transurethral Resection for T1 Non-muscle invasive Bladder Cancer: A Systematic Review and Meta-analysis.
Eur Urol Focus. 2018 Jul;4(4):558-567. doi: 10.1016/j.euf.2016.12.011. Epub 2017 Jan 13.
6
8
Prognostic significance of markers of systemic inflammatory response in patients with non-muscle-invasive bladder cancer.
Urol Oncol. 2016 Nov;34(11):483.e17-483.e24. doi: 10.1016/j.urolonc.2016.05.013. Epub 2016 Sep 16.
10
Repeated transurethral resection for non-muscle invasive bladder cancer.
Int J Clin Exp Med. 2015 Jan 15;8(1):1416-9. eCollection 2015.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验